...
search icon
cvac-img

CureVac NV, Common Stock

CVAC

NMQ

$3.65

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$818.83M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
7.449
Volume info-icon
This is the total number of shares traded during the most recent trading day.
420.10K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.61
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.21 L
$5.28 H
$3.65

About CureVac NV, Common Stock

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCVACSectorS&P500
1-Week Return1.96%-0.03%1.53%
1-Month Return-7.36%4.56%4.75%
3-Month Return36.7%1.29%2.77%
6-Month Return10.27%-3.54%12.18%
1-Year Return6.41%1.59%22.34%
3-Year Return-77.8%13.55%38.91%
5-Year Return-93.47%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue17.42M48.90M102.99M67.42M53.76M[{"date":"2019-12-31","value":16.91,"profit":true},{"date":"2020-12-31","value":47.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.46,"profit":true},{"date":"2023-12-31","value":52.2,"profit":true}]
Cost of Revenue27.98M14.17M238.19M183.99M124.37M[{"date":"2019-12-31","value":11.75,"profit":true},{"date":"2020-12-31","value":5.95,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.24,"profit":true},{"date":"2023-12-31","value":52.21,"profit":true}]
Gross Profit(10.57M)34.73M(135.21M)(116.57M)(70.61M)[{"date":"2019-12-31","value":-30.43,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-389.34,"profit":false},{"date":"2022-12-31","value":-335.68,"profit":false},{"date":"2023-12-31","value":-203.32,"profit":false}]
Gross Margin(60.67%)71.02%(131.28%)(172.91%)(131.34%)[{"date":"2019-12-31","value":-85.44,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-184.86,"profit":false},{"date":"2022-12-31","value":-243.47,"profit":false},{"date":"2023-12-31","value":-184.95,"profit":false}]
Operating Expenses88.93M158.70M277.06M134.28M203.60M[{"date":"2019-12-31","value":32.1,"profit":true},{"date":"2020-12-31","value":57.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":48.47,"profit":true},{"date":"2023-12-31","value":73.49,"profit":true}]
Operating Income(99.50M)(124.00M)(412.26M)(249.46M)(274.21M)[{"date":"2019-12-31","value":-9949800000,"profit":false},{"date":"2020-12-31","value":-12400200000,"profit":false},{"date":"2021-12-31","value":-41226300000,"profit":false},{"date":"2022-12-31","value":-24945700000,"profit":false},{"date":"2023-12-31","value":-27420700000,"profit":false}]
Total Non-Operating Income/Expense(1.25M)(40.03M)(470.00K)604.00K19.71M[{"date":"2019-12-31","value":-6.36,"profit":false},{"date":"2020-12-31","value":-203.11,"profit":false},{"date":"2021-12-31","value":-2.38,"profit":false},{"date":"2022-12-31","value":3.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(100.13M)(129.80M)(412.50M)(249.16M)(259.97M)[{"date":"2019-12-31","value":-10012500000,"profit":false},{"date":"2020-12-31","value":-12980000000,"profit":false},{"date":"2021-12-31","value":-41249800000,"profit":false},{"date":"2022-12-31","value":-24915500000,"profit":false},{"date":"2023-12-31","value":-25996900000,"profit":false}]
Income Taxes(252.00K)(726.00K)(782.00K)(126.00K)198.00K[{"date":"2019-12-31","value":-127.27,"profit":false},{"date":"2020-12-31","value":-366.67,"profit":false},{"date":"2021-12-31","value":-394.95,"profit":false},{"date":"2022-12-31","value":-63.64,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(99.87M)(129.07M)(411.72M)(249.03M)(260.17M)[{"date":"2019-12-31","value":-9987300000,"profit":false},{"date":"2020-12-31","value":-12907400000,"profit":false},{"date":"2021-12-31","value":-41171600000,"profit":false},{"date":"2022-12-31","value":-24902900000,"profit":false},{"date":"2023-12-31","value":-26016700000,"profit":false}]
Income From Continuous Operations(99.87M)(129.80M)(411.72M)(249.03M)(302.30M)[{"date":"2019-12-31","value":-9987300000,"profit":false},{"date":"2020-12-31","value":-12980000000,"profit":false},{"date":"2021-12-31","value":-41171600000,"profit":false},{"date":"2022-12-31","value":-24902900000,"profit":false},{"date":"2023-12-31","value":-30229800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(99.87M)(129.07M)(411.72M)(249.03M)(260.17M)[{"date":"2019-12-31","value":-9987300000,"profit":false},{"date":"2020-12-31","value":-12907400000,"profit":false},{"date":"2021-12-31","value":-41171600000,"profit":false},{"date":"2022-12-31","value":-24902900000,"profit":false},{"date":"2023-12-31","value":-26016700000,"profit":false}]
EPS (Diluted)-(0.91)-(3.23)(1.21)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-91,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-322.5,"profit":false},{"date":"2023-12-31","value":-121,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CVAC
Cash Ratio 5.88
Current Ratio 6.20
Quick Ratio 6.19

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CVAC
ROA (LTM) -24.52%
ROE (LTM) -54.30%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CVAC
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CVAC
Trailing PE 7.45
Forward PE 5.24
P/S (TTM) 12.43
P/B 1.09
Price/FCF 2
EV/R 0.49
EV/Ebitda 1.62

FAQs

What is CureVac NV share price today?

CureVac NV (CVAC) share price today is $3.65

Can Indians buy CureVac NV shares?

Yes, Indians can buy shares of CureVac NV (CVAC) on Vested. To buy CureVac NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CVAC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of CureVac NV be purchased?

Yes, you can purchase fractional shares of CureVac NV (CVAC) via the Vested app. You can start investing in CureVac NV (CVAC) with a minimum investment of $1.

How to invest in CureVac NV shares from India?

You can invest in shares of CureVac NV (CVAC) via Vested in three simple steps:

  • Click on Sign Up or Invest in CVAC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in CureVac NV shares
What is CureVac NV 52-week high and low stock price?

The 52-week high price of CureVac NV (CVAC) is $5.28. The 52-week low price of CureVac NV (CVAC) is $2.21.

What is CureVac NV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of CureVac NV (CVAC) is 7.449

What is CureVac NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of CureVac NV (CVAC) is 1.09

What is the Market Cap of CureVac NV?

The market capitalization of CureVac NV (CVAC) is $818.83M

What is CureVac NV’s stock symbol?

The stock symbol (or ticker) of CureVac NV is CVAC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top